Evidence map›Paper›PMID 40934005›Full record

ArticleFrontiers in immunology2025

Prediction and effect on relapse of natural killer cell alloreactivity based on KIR-HLA interactions in pediatric haploidentical transplantation with anti-thymoglobulin.

Xiang-Feng Tang, Yan-Hui Luo, Ying-Jian Si, Mao-Quan Qin, Wei Lu, Wei Chen, Guo-Sheng Xing, Wei Cao, Hai-Fei Zhou, Xiang-Jun Liu

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiang-Feng Tang *National Engineering Laboratory for Birth Defects Prevention and Control of Key Technology, Beijing Key Laboratory of Pediatric Organ Failure, Department of Pediatrics, The Seventh Medical Center of PLA General Hospital, Beijing, China.
Yan-Hui Luo *Department of Hematology and Oncology, Beijing Children's Hospital, Capital Medical University, Beijing, China.
Ying-Jian SiNational Engineering Laboratory for Birth Defects Prevention and Control of Key Technology, Beijing Key Laboratory of Pediatric Organ Failure, Department of Pediatrics, The Seventh Medical Center of PLA General Hospital, Beijing, China.
Mao-Quan QinDepartment of Hematology and Oncology, Beijing Children's Hospital, Capital Medical University, Beijing, China.
Wei LuNational Engineering Laboratory for Birth Defects Prevention and Control of Key Technology, Beijing Key Laboratory of Pediatric Organ Failure, Department of Pediatrics, The Seventh Medical Center of PLA General Hospital, Beijing, China.
Wei ChenNational Engineering Laboratory for Birth Defects Prevention and Control of Key Technology, Beijing Key Laboratory of Pediatric Organ Failure, Department of Pediatrics, The Seventh Medical Center of PLA General Hospital, Beijing, China.
Guo-Sheng XingNational Engineering Laboratory for Birth Defects Prevention and Control of Key Technology, Beijing Key Laboratory of Pediatric Organ Failure, Department of Pediatrics, The Seventh Medical Center of PLA General Hospital, Beijing, China.
Wei CaoNational Engineering Laboratory for Birth Defects Prevention and Control of Key Technology, Beijing Key Laboratory of Pediatric Organ Failure, Department of Pediatrics, The Seventh Medical Center of PLA General Hospital, Beijing, China.
Hai-Fei ZhouBeijing BFR Gene Diagnostics, Beijing, China.
Xiang-Jun LiuBeijing BFR Gene Diagnostics, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Relapse continues to be a major factor contributing to therapeutic failure in haploidentical hematopoietic stem cell transplantation (HSCT). The role of natural killer (NK) cell alloreactivity mediated by killer immunoglobulin-like receptors (KIRs) is considered important in postoperative immune reconstitution and in mitigating relapse. However, its clinical implications remain incompletely defined, and its impact on allogeneic HSCT is controversial across studies. Methods: In the present investigation, we assessed the effect of predicted NK cell alloreactivity through KIR-ligand interactions on relapse and survival outcomes in a pediatric cohort. This retrospective study included pediatric patients who underwent their first haploidentical HSCT following the Beijing protocol between 2013 and 2023. Both low- and high-resolution typing methods were employed for all donor and patient samples. The presence of NK cell alloreactivity was determined using predictive models incorporating the HLA class I molecules of both donors and recipients. NK cell alloreactivity was classified as ALLO or Non-ALLO based on the presence or absence of predicted alloreactivity, and its effects on relapse and overall survival were evaluated through individual and combinatorial interactions. Results: Multivariate analysis demonstrated that, among patients lacking A3/A11, those who received grafts from donors with both KIR3DL2+ and A3/A11+ had an 86% lower risk of relapse (adjusted hazard ratio 0.136; p = 0.0489). Both Synthesis-iKIR and combined Synthesis-iKIR/KIR2DS1 showed significant independent effects on overall survival, with clinically adjusted hazard ratios of 0.305 and 0.316 (p < 0.005), respectively. The disease state at transplantation was an independent clinical factor influencing prognosis. Other additive models failed to effectively predict clinical outcomes in pediatric recipients. Discussion: These results indicate that pediatric patients exhibiting NK cell alloreactivity, as predicted by the KIR3DL2-A3/A11 combination, had a significantly lower cumulative incidence of relapse. Furthermore, alloreactivity predicted by Synthesis-iKIR was significantly associated with improved overall survival. These findings have not been previously validated in pediatric studies and may have clinical relevance for haploidentical transplantation population, pending confirmation in larger cohorts.

Indexed as

Antilymphocyte SerumHematopoietic Stem Cell TransplantationHLA AntigensKiller Cells, NaturalReceptors, KIRTransplantation, HaploidenticalAdolescentChildChild, PreschoolFemaleGraft vs Host DiseaseHumansInfantMaleRecurrenceRetrospective StudiesAntilymphocyte SerumHLA AntigensReceptors, KIRthymoglobulinallogeneic hematopoietic stem cell transplantationclinical outcomeeducational modelkiller immunoglobulin-like receptorpediatric haploidentical transplantation

Identifiers

PMID40934005
PMCPMC12417149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.